109 related articles for article (PubMed ID: 1592363)
1. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma.
Drach J; Gattringer C; Glassl H; Drach D; Huber H
Hematol Oncol; 1992; 10(2):125-34. PubMed ID: 1592363
[TBL] [Abstract][Full Text] [Related]
2. [Proliferative activity of myeloma cells determined by Ki-67 antibody: biological and clinical significance].
Marković O; Marisavljević D; Cemerikić V; Vidović A; Bakrac M; Perunicić M; Suvajdzić N; Colović M
Vojnosanit Pregl; 2005 Jan; 62(1):33-8. PubMed ID: 15715347
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.
Thaler J; Fechner F; Herold M; Huber H
Leuk Lymphoma; 1994 Jan; 12(3-4):265-71. PubMed ID: 8167557
[TBL] [Abstract][Full Text] [Related]
4. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
5. [Determination proliferative activity of myeloma cells in histologic material].
Fabian P; Kren L; Nenutil R
Cesk Patol; 2004 Apr; 40(2):46-9. PubMed ID: 15233016
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections.
Pellegrini W; Facchetti F; Marocolo D; Salvi L; Capucci A; Tironi A; Rossi G
Histopathology; 1995 Nov; 27(5):397-405. PubMed ID: 8575729
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma.
Alexandrakis MG; Passam FH; Kyriakou DS; Dambaki K; Niniraki M; Stathopoulos E
Am J Clin Oncol; 2004 Feb; 27(1):8-13. PubMed ID: 14758126
[TBL] [Abstract][Full Text] [Related]
9. Tumor proliferative fraction in solid malignant neoplasms. A comparative study of Ki-67 immunostaining and flow cytometric determinations.
Sahin AA; Ro JY; el-Naggar AK; Wilson PL; Teague K; Blick M; Ayala AG
Am J Clin Pathol; 1991 Oct; 96(4):512-9. PubMed ID: 1716414
[TBL] [Abstract][Full Text] [Related]
10. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.
Alexandrakis MG; Passam FH; Dambaki C; Pappa CA; Stathopoulos EN
J Clin Pathol; 2004 Aug; 57(8):856-60. PubMed ID: 15280408
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies.
Girino M; Riccardi A; Luoni R; Ucci G; Cuomo A
Acta Haematol; 1991; 85(1):26-30. PubMed ID: 2011926
[TBL] [Abstract][Full Text] [Related]
12. Cytometric ploidy and proliferative activity in colorectal carcinoma.
Grigolato P; Berenzi A; Benetti A; Chirico E; Cadei M; Casella C; Salerni B; Lojacono L
Eur J Histochem; 1994; 38(2):163-70. PubMed ID: 7524813
[TBL] [Abstract][Full Text] [Related]
13. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysis.
Kawai T; Suzuki M; Kono S; Shinomiya N; Rokutanda M; Takagi K; Ogata T; Tamai S
Cancer; 1994 Nov; 74(9):2468-75. PubMed ID: 7923002
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 Immunostaining and its Correlation with Microvessel Density in Patients with Mutiple Myeloma.
Himani B; Meera S; Abhimanyu S; Usha R
Asian Pac J Cancer Prev; 2016; 17(5):2559-64. PubMed ID: 27268630
[TBL] [Abstract][Full Text] [Related]
15. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.
Isola J; Kallioniemi OP; Korte JM; Wahlström T; Aine R; Helle M; Helin H
J Pathol; 1990 Dec; 162(4):295-301. PubMed ID: 2290114
[TBL] [Abstract][Full Text] [Related]
16. The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma.
Musto P; Lombardi G; Matera R; Carotenuto M
Haematologica; 1991; 76(6):513-6. PubMed ID: 1687943
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.
García-Sanz R; Orfão A; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Br J Haematol; 1995 May; 90(1):106-12. PubMed ID: 7786771
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 and proliferating cell nuclear antigen tumor proliferative indices in DNA diploid colorectal adenocarcinomas. Correlation with histopathologic characteristics and cell cycle analysis with two-color DNA flow cytometry.
Linden MD; Ma CK; Kubus J; Brown RD; Zarbo RJ
Am J Clin Pathol; 1993 Sep; 100(3):206-12. PubMed ID: 8104388
[TBL] [Abstract][Full Text] [Related]
19. Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma.
Fosså A; Brandhorst D; Myklebust JH; Seeber S; Nowrousian MR
Exp Hematol; 1999 Nov; 27(11):1621-6. PubMed ID: 10560909
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Sahara N; Takeshita A; Shigeno K; Fujisawa S; Takeshita K; Naito K; Ihara M; Ono T; Tamashima S; Nara K; Ohnishi K; Ohno R
Br J Haematol; 2002 Jun; 117(4):882-5. PubMed ID: 12060125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
